From: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer
Cohort | % AP4- | 5 year survival (95% CI) | 10 year survival (95% CI) | Hazard ratio (95% CI) | Logrank p-value |
---|---|---|---|---|---|
OXFD+ | 38% | 0.96 (0.90 – 1.00) | 0.93 (0.86 – 1.00) | 6.73 (2.02 – 22.4) | 3 × 10-4 |
MZ+ | 47% | 0.92 (0.86 – 0.98) | 0.85 (0.75 – 0.95) | 2.23 (1.02 – 4.87) | 0.039 |
GUYT+ | 31% | 0.96 (0.89 – 1.00) | 0.88 (0.76 – 1.00) | 3.09 (0.90 – 10.5) | 0.058 |
GUYT2+ | 36% | No metastases in AP4- | Â | Â | Â |
TOTAL | 40% | 0.95 (0.93 – 0.98) | 0.89 (0.85 – 0.93) | 3.76 (2.16 – 6.56) | 5.14 × 10-7 |